Related Experiment Video
Updated: Oct 6, 2025
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities
Camilla Calandrini1,2, Jarno Drost1,2
1Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Abstract:
Patient-derived tumor organoids can be predictive of patient's treatment responses, and normal tissue-derived organoids allow for drug toxicity testing. Combining both types of organoids therefore enables screening for tumor-specific drug vulnerabilities. Here, we provide a detailed protocol for organoid drug screening using, as proof-of-principle, patient-derived malignant rhabdoid tumor organoids. The protocol can be adapted for drug testing on any tumor and/or normal tissue-derived organoid culture. For complete details on the use and execution of this protocol, please refer to Calandrini et al. (2021).
Insights
This study presents a protocol for organoid drug screening. Patient-derived tumor organoids predict treatment response, while normal tissue organoids assess drug toxicity, enabling personalized cancer therapy development.
Area of Science:
- Oncology
- Drug Discovery
- Biotechnology
Background:
- Patient-derived tumor organoids accurately predict clinical treatment responses.
- Normal tissue-derived organoids are valuable for assessing drug toxicity.
- Combining these organoid models allows for effective screening of tumor-specific drug vulnerabilities.
Purpose of the Study:
- To provide a detailed protocol for organoid-based drug screening.
- To demonstrate the application of this protocol using patient-derived malignant rhabdoid tumor organoids.
- To offer a adaptable method for drug testing on diverse organoid cultures.
Main Methods:
- Development of a comprehensive protocol for organoid drug screening.
- Utilizing patient-derived malignant rhabdoid tumor organoids as a proof-of-principle model.
- Adaptation of the protocol for both tumor and normal tissue organoid cultures.
Main Results:
- Established a detailed and adaptable protocol for organoid drug screening.
- Successfully applied the protocol to patient-derived malignant rhabdoid tumor organoids.
- Demonstrated the potential for screening tumor-specific drug vulnerabilities.
Conclusions:
- The presented protocol enables predictive drug screening using patient-derived organoids.
- This method facilitates the identification of targeted therapies with minimal toxicity.
- The protocol is versatile and applicable to various organoid models for personalized medicine.
